Developing innovative therapies for the treatment of respiratory diseases

August 2024

Verona Pharma®
Breath of Innovation

Nasdaq: VRNA | www.veronapharma.com

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation other than statements of historical fact should be considered forward-looking statements. Words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “may,” “potential,” “prepare,” “possible” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the potential benefits, efficacy, and approval of our drug Ohtuvayre™, including, but not limited to, statements relating to the potential to change the treatment paradigm for COPD patients, the anticipated timing of commercial availability and our ability to successfully market and sell Ohtuvayre.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of Ohtuvayre which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; our reliance on the success of Ohtuvayre, our only commercial product; our reliance on third-party manufacturers and suppliers; the efficacy of Ohtuvayre™ compared to competing drugs; our ability to successfully commercialize Ohtuvayre; serious adverse, undesirable or unacceptable side effects associated with Ohtuvayre which could adversely affect our ability to commercialize Ohtuvayre; failure to develop Ohtuvayre for additional indications, alternate delivery methods, or as a combination therapy; failure to obtain approval for and commercialize Ohtuvayre in multiple major pharmaceutical markets; lawsuits related to patents covering Ohtuvayre and the potential for our patents to be found invalid or unenforceable; lawsuits related to our licensing of patents and know-how from third parties for the commercialization of Ohtuvayre; changes in our tax rates, unavailability of certain tax credits or reliefs or exposure to additional tax liabilities or assessments that could affect our profitability, and audits by tax authorities that could result in additional tax payments for prior periods; and our vulnerability to natural disasters, global economic factors, geo-political actions and unexpected events, including health epidemics or pandemics. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on May 10, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

Strong financial position to support company growth

Future draws up to $425M provide optionality beyond 2026[1]

$404.6M
Cash and equivalents
June 30, 2024

~$37.0M[2]
Operating expenses
June 30, 2024

$1.7B[4]
Market Cap
(Nasdaq: VRNA)
August 2, 2024

Potential future draws

- **$275M** under $400M debt facility
- **$150M** under $250M Revenue Interest Purchase and Sale Agreement[3]

1 - Runway expectations based on cash and equivalents as of June 30, 2024, and future draws on Oaktree/OMERS debt facility and RIPSA.
2 - Operating expenses for 2Q 2024 shown net of non-recurring one-time expenses related to milestone payments and PRSUs tied to the US FDA approval and commercial launch of Ohtuvayre.
3 - Repayment capped at 1.75x of the amount funded.
4 - Approximately 81.1M ADSs outstanding as of as of Aug 2, 2024 (equivalent to ~ 648.7M ordinary shares).

Verona Pharma®

Verona Pharma's respiratory product pipeline

Ensifentrine provides multiple product opportunities

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Approved/ Available
Ensifentrine (Nebulizer)	Maintenance treatment of COPD					
	Non-Cystic Fibrosis bronchiectasis					
	Cystic Fibrosis					
	Asthma					
Ensifentrine + LAMA (Nebulizer)	Maintenance treatment of COPD					
Ensifentrine (DPI / MDI)	Maintenance treatment of COPD					
	Asthma					
	Cystic Fibrosis					

LAMA: Long-acting muscarinic agent
DPI: Dry powder inhaler, pMDI: Pressurized metered-dose inhaler

Verona Pharma®

Ohtuvayre™ is available for the maintenance treatment of COPD in adult patients

Label supports broad use in COPD patients

Broad Use / Novel MOA

Pre-commercial activities set the stage for rapid launch

Commercial team / infrastructure driving Launch

First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects

Ohtuvayre prescribing information

Verona Pharma®

Ensifentrine: Novel selective inhibitor of PDE3 and PDE4

Downstream bronchodilation and non-steroidal anti-inflammatory effects

PDE3 and PDE4 enzymes are present in lung cells associated with COPD pathology:



Selective inhibition of PDE3 and PDE4 results in accumulation of intracellular levels of signaling molecules, cAMP and cGMP



This mechanism of action produces:

- Bronchodilation
- Decreased inflammatory response
- Increased ciliary function

cAMP = cyclic adenosine monophosphate; cGMP = cyclic guanosine monophosphate; PDE3 = phosphodiesterase 3; PDE4 = phosphodiesterase 4.

[1]Calzetta L, et al., J Pharmacol Exp Ther. 2013;346(3); [2]Calzetta L, et al., Pulm Pharmacol Ther 2015;32:15-23; [3]Matera MG, et al., Am J Respir Crit Care Med 2013;187:A1495; [4]Venkatasamy R, et al., Br J Pharmacol 2016;173(15):2335-2351; [5]Boswell-Smith V, et al., J Pharmacol Exp Ther 2006;318(2):840-848; [6]Franciosi LG, et al., Lancet Respir Med 2013;1(9):714-727; [7]Schmidt D, et al., Br J Pharmacol 2000;131(8):1607-1618; [8]Turner MJ, et al., Am J Physiol Lung Cell Mol Physiol 2016;310(1):L59-70

Verona Pharma®

Phase 3 data published in *American Journal of Respiratory and Critical Care Medicine*

Endpoint	ENHANCE-1 (N=760)	ENHANCE-2 (N=789)
Average FEV_1 AUC (0-12 hours)	+87 mL (p<0.0001) vs placebo	+94 mL (p<0.0001) vs placebo
Peak FEV_1	+147 mL (p<0.0001) vs placebo	+146 mL (p<0.0001) vs placebo
Morning Trough FEV_1	+35 mL (p=0.0413) vs placebo	+49 mL vs placebo[a]
Symptoms (E-RS Total Score) **Quality of Life (SGRQ Total Score)**	-1.0 units (p=0.0111) vs placebo -2.3 units (p=0.0253) vs placebo	-0.6 units vs placebo[b] -0.5 units vs placebo[b]
Exacerbation rate **Time to first COPD exacerbation**	36% reduction in rate[c] 38% reduction in risk[c]	43% reduction in rate[c] 42% reduction in risk[c]
Incidence of adverse events (AEs ≥1% and greater than placebo)	Back Pain 1.8% vs 1.0% Hypertension 1.7% vs 0.9% UTI 1.3% vs 1.0% Diarrhea 1.0% vs 0.7%	

[a] Result was not statistically significant due to failure higher in the analysis hierarchy
[b] Not significant
[c] Pre-specified other endpoints were not part of the formal testing hierarchy
UTI = Urinary tract infection

[1]*Anzueto A, et al. Am J Respir Crit Care Med. 2023;208(4):406-416;* [2]*Barjaktarevic I, et al. Am J Respir Crit Care Med. 2023;207:A5008*

Verona Pharma®

Pipeline expansion : Non-cystic fibrosis bronchiectasis (NCFBE)

Chronic disease marked by recurrent infection and progressive lung damage

~370,000 US Patients[1,2]
No Approved Treatments

Key Issues

- Exacerbations (neutrophilic driven)
- Cough & sputum production

Unmet Needs

- High level of unmet need due to lack of approved options
- Anti-inflammatory drugs (international guidelines on bronchiectasis discourage use of corticosteroids)

Ensifentrine Targets Neutrophilic Inflammation, Impacts Exacerbations & Key NCFBE Symptoms



[1]*Prevalence calculated by US Census data and prevalence rate of NCFBE;* [2]*Non-Cystic Fibrosis Bronchiectasis (NCFBE) Market Insights, Epidemiology and Market Forecast – 2032, Delveinsight*

Verona Pharma®

Bronchiectasis Phase 2 Design



Primary endpoint: Protocol-defined pulmonary exacerbation rate

Secondary endpoints:

- Time to first pulmonary exacerbation
- Patient Reported Outcomes: E-RS cough and sputum domain, QoL-B (respiratory), SGRQ, CAAT
- Lung function (pre and post-dose)

CAAT: Chronic Airways Assessment Test; EOS: End of study; EOT: End of treatment; E-RS: Evaluating Respiratory Symptoms; QoL-B: Quality of Life Bronchiectasis; SGRQ: St. George's Respiratory Questionnaire; TS: Treatment start; V: Visit

Verona Pharma®

Pipeline expansion: Fixed dose combination

COPD market has progressed to combination products to maximize efficacy given chronic, progressive disease

Rationale for Ensifentrine + Glycopyrrolate

- Synergistic effect demonstrated on bronchial smooth muscle and isolated bronchi with ensifentrine + glycopyrrolate[1]
- >400 subject Phase 2b study completed with ensifentrine added on to a LAMA[2]
- >400 subjects were dosed with ensifentrine or placebo + LAMA in the ENHANCE program over 24 weeks
- Data supports strong improvement in lung function, symptoms, QoL and exacerbations added on to a LAMA[3]
- Combines 2 bronchodilator mechanisms with non-steroidal anti-inflammatory effects

Phase 2 program design supports dose selection for Phase 3

- **Glycopyrrolate dose ranging (n=40, >80% power)**
  - 4 x 1 week treatment periods with 1 week washouts
  - 3 doses + placebo
  - Endpoints: Day 7 Trough FEV_1, peak FEV_1, average FEV_1 AUC_{0-12}
- **Fixed-dose combination versus glycopyrrolate and ensifentrine individual components (n=480, >80% power)**
  - 4 week parallel group design
  - 6 dose arms: 2 combination doses + 3 individual component arms + placebo
  - Endpoints: Week 4 average FEV_1 $AUC_{0-4,}$ peak FEV_1 average FEV_1 AUC_{0-12}, COPD symptoms

[1]Calzetta L, et al. Pulm Pharmacol Ther. 2015 Jun;32:15-23; Calzetta L, et al. J Pharmacol Exp Ther. 2013 Sep;346(3):414-23. [2]Spiriva Respimat; Ferguson G, et al. Int J Chron Obstruct Pulmon Dis. 2021 Apr 22;16:1137-1148; [3]Siler, T M, et al. CHEST. 2023 Oct 1;164(4):A4952-4

Verona Pharma®

Ohtuvayre™
Commercial Opportunity

Verona Pharma®
Breath of Innovation

COPD patients need new treatment options[1,2]

~50% of patients remain persistently symptomatic

~8.6M Maintenance Treated COPD Patients[3]

50%

Persistently Symptomatic COPD Patients Regardless of Therapy[2]

Persistent Symptoms drive referrals to Pulmonologists

~4.3M

Persistently symptomatic patients

Launch Focus

Ohtuvayre™ (ensifentrine) Inhalation Suspension

3 mg/2.5 mL

[1]Chen, et al., Int J Chron Obstruct Pulmon Dis. 2018;13:1365-1376; [2]Phreesia COPD Patient Perceptions Survey; [3]Data on File – Forecast Project

Verona Pharma®

HCPs have high willingness to use Ohtuvayre™ across all COPD patient groups[1]



80%* Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL ***Overall Intent to Prescribe***

HCPs intent to Prescribe Ohtuvayre™

Market Research Question: assume this patient was complaining of the following symptoms. Based on their clinical characteristics and current treatment, would you consider **prescribing Product X** to this patient, assuming it is now available?
TPP Tested consistent with current label

[1]*Data on File ATU 2024*

Verona Pharma®

Patients have significant symptom burden and want different treatment options

Patients are motivated by Ohtuvayre™ profile

>50% patients report persistent monthly symptoms[1,2]

~75% patients use a nebulizer at home[3]

High motivation to try / ask HCP about novel, steroid free COPD treatment[4]

[1]Chen, et al., Int J Chron Obstruct Pulmon Dis. 2018;13:1365-1376; [2]Phreesia COPD Patient Perceptions Survey; [3]Data on File – Patient Research Sept 2023; [4]Data on File – ATU 2024

Verona Pharma®

Medical benefit primary reimbursement pathway for Ohtuvayre™

All requirements for reimbursement and payers in place for patient access

Medical Benefit Reimbursement[1]



Payers

All clinical presentations completed with key payers

J7699 non-specific inhalation J-Code at launch

J-Code submitted and expected Jan 1, 2025

[1]*Data on file - Forecast Project*

Verona Pharma®

Verona is promoting to the most active HCPs

Ohtuvayre™ promotion through a variety of channels



	Tier 1	Tier 2	Tier 3	Tier 4
HCP Count	~2,500	~12,000	~25,000	~360,000
Monthly COPD TRx	>160	>50	~20	~3

*Data source: Data on File - Claims; Time Period: Calendar Year 2023

Verona Pharma®

Verona Pathway Plus™ Ensuring patient access and customer support

HUB Partner

CareMetx

Exclusive Accredited Pharmacy Partners

AcariaHealth Specialty Pharmacy

CVS specialty™

CenterWell Specialty Pharmacy

DirectRx PHARMACY

Prescription Fulfillment

- 98% of patient lives covered
- Verona Care Coordinator & Field Reimbursement Team

Coverage and Affordability

- Benefit verification
- Prior authorization / appeals assistance
- Financial support resources for eligible patients

Support and Education

- Ongoing education and treatment support
- 24/7 access to clinical pharmacist

Verona Pharma®

Ohtuvayre™ pricing reflects benefit to patient and overall value to the health system

COPD is a costly disease to the health system

~$50B	Annual direct and indirect costs of COPD[1]
~$26k	Healthcare associated costs per exacerbation[2]

Cost-Effectiveness Modeling highlights Ohtuvayre value

~$1k – $5k*

Various cost effectiveness models (Net monthly cost*)[3,4]

Ohtuvayre Price

$2,950	WAC price (monthly)

*monthly cost where Ohtuvayre offsets healthcare costs

[1]CDC International Journal of Chronic Obstructive Pulmonary Disease, 2020 Iheanancho et. al.; [2]Bogart et al. Am J Manag Care. 2020;26:e150-e154; [3]Data on File – Pricing Project 2024; [4]ICER 2024 draft report

Verona Pharma®

Ohtuvayre: Multi-billion dollar opportunity

Ohtuvayre™ can be used in all symptomatic COPD patients regardless of background therapy

Ohtuvayre Opportunity

Market Size	~8.6M[1] Treated Patients
Pricing / Month	$2,950[2]
Months of Therapy / Year	6
GtN Discount	25%

Every 1%
share of treated patients

~$1.1B
Net revenue

Current COPD Patient Shares[3]

21%	Symbicort® (LABA/ICS)
12%	Trelegy (LAMA/LABA/ICS)
11%	Spiriva® (LAMA)
5%	Anoro (LAMA/LABA)
1%	Daliresp® (PDE4)

[1]Data on File – Forecast Project; [2]Verona WAC Price ; [3]Data on File – Patient Claims

Verona Pharma®

Ensifentrine strategy in ROW

Strategic collaborations to maximize ensifentrine's commercial value

United States:
~$10B in Sales[1]

Ohtuvayre™ Available

Prevalence of COPD in US:
~8.6M treated chronically[2]

China:
~$1B in Sales
(expected to double by 2030) [1]

~1B in sales (expected to double by 2030)[1]

EU:
~$2B Euros in Sales (2020)[1]

~2B Euros in sales (2020)[1]

[1]As of year end 2021, IQVIA MIDAS, IQVIA MIDAS Medical; [2]Data on File – Forecast Project

Verona Pharma®

Patent protection through the mid 2030s

3 Orange Book-listed patents; 6 more potentially eligible

Invention	Granted/Pending Application	Estimated Patent Expiry
Polymorph*	Granted US, Europe, China, Japan, other	2031
Ensifentrine Suspension formulation*	Granted US, Europe, China, Japan, other	2035
Ensifentrine Suspension Formulation – Low PH buffer*	Granted US, Europe, China, Japan, other	2035
Manufacturing process	Granted Europe, US, China, Japan, other	2037
Combinations with anti-muscarinics	Granted US, Europe, China, Japan, other	2034
Ensifentrine/glycopyrrolate formulation	Granted Europe, UK, other. Pending US, China, Japan	2041
Treatment of moderate COPD**	Pending US and PCT application	2043
Trough lung function**	Pending US and PCT application	2043
Reduction in COPD exacerbation**	Pending US and PCT application	2043
PK Profile**	Pending US and PCT application	2043
Renal impairment**	Pending US. PCT	2045
Purity Profile**	Pending UK, Taiwan, US and PCT application	2044

* Patents Orange Book listed

**Patents potentially eligible for Orange Book listing

Up to 5 years potential patent term extension on select patent

Verona Pharma®

Verona poised for successful Ohtuvayre™ launch

Large Market with significant unmet need

- *Millions of patients remain symptomatic and unsatisfied with current therapies[1-5]*
- *Novel MOAs needed to treat progressive disease*

Ohtuvayre is available

- *~120 field facing personnel, infrastructure and systems established to support launch*
- *Active field promotion to tier 1 and 2 HCPS*

Reimbursement pathway to ensure early access

- *Reimbursement primarily through medical benefit*
- *Verona Pathway Plus™ supporting access*

People and financial resources to support launch

- *Cash runway beyond 2026*

[1]Ferguson et al. Lancet Respir Med 2018;6:747-58; [2]Mahler D, et al., Eur Respir J, 2014;43:1599-1609; [3]Vestbo J, et al., The Lancet, 2017;389:19-29; [4]Verona I US MCOPD Integrated Conjoint Survey; [5]Phreesia COPD Patient Survey 2022; [6]Verona_IQVIA_LAAD Quarterly Reporting Report 2_June 2022 - Data for MAT Dec 2021

Verona Pharma®

Thank you

Verona Pharma®
Breath of Innovation